Tiganis
Laboratory
Cellular Signalling
& Human Disease
Welcome to the Tiganis Lab
The Tiganis lab investigates the signalling pathways underlying the pathophysiology of obesity, type 2 diabetes and complications such as liver disease and cancer.
We're part of the Monash Biomedicine Discovery Institute and a member of the Cancer, Metabolism, Diabetes & Obesity and Immunity Programs, and the Department of Biochemistry and Molecular Biology.
Professor Tony Tiganis
My global research connections, partners and funding can be viewed on my Monash Research Profile.
If you are a student interested in doing research in our lab, visit Supervisor Connect.
Click the links below to connect with me on Twitter, ORCID, Google Scholar and LinkedIn.
Our research
The Tiganis lab investigates the signalling pathways underpinning the development of obesity, type 2 diabetes and co-morbidities, including non-alcoholic fatty liver disease and cancer.
Obesity has now reached epidemic proportions and is the single most important driver of morbidity and mortality in the modern world. Obesity is a key contributor to a myriad of human diseases including type 2 diabetes, cardiovascular disease, autoimmune diseases, liver disease, chronic kidney diseases and some 13 different cancers.
At present, more than a quarter of the world’s population is overweight. Educational and lifestyle intervention approaches have done little to curb the escalating trend toward the overweight and obese state. Thus, it is imperative that we develop new therapies to assist with weight loss, as well as specific therapies for the diseases that obesity triggers.
Our goal is to dissect the molecular mechanisms and develop new therapies for obesity and its comorbidities.
-
CNS and peripheral mechanism governing energy balance and glucose homeostasis
Our research investigates mechanisms and how these are influenced -by stress and with age - to contribute to the development of obesity and type 2 diabetes.
-
Obesity, NAFLD and liver cancer
Our research aims to understand how obesity promotes the development of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH)/fibrosis and hepatocellular carcinoma (HCC).
-
The influence of obesity on cancer and immunotherapy
Our research aims to understand how obesity influences the development and treatment of cancer and the extent to which this involves changes in the immune system.
Lab members
We are committed to excellence in research.
Join Our Lab
We're always interested in collaborating with bright and motivated researchers, clinicians and industry. Whether you want to research, study or partner with us to accelerate our discoveries, find out about the work we do.